6
Oct
2026
AqVida GmbH
Exhibitor at CPHI Milan 2026 stand 16C1, Finished Dosage & Formulation
About Us
Categories
-
Country/Region:Germany
-
On CPHI since:2015
-
Certificates:2
-
Employees:50 - 99
Company types
Contact info
-
-
-
Kaiser-Wilhelm-Str. 89, D-20355 , Hamburg, Germany
Event information
CPHI Milan 2026
-
6 Oct 2026 - 8 Oct 2026
-
Fiera Milano, Italy
-
Visit us at stand 16C1, Finished Dosage & Formulation
Products Featured at CPHI Milan 2026
-
Product Azathioprine AqVida film-coated tablets
25 mg, 50 mg Tablets Immunosuppressant -
Product Docetaxel AqVida 20 mg/ml concentrate for solution for infusion
20 mg, 80 mg, 140 mg, 160 mg vial Indications: Treatment of breast cancer, special form of lung cancer, prostate cancer, gastric cancer and head or neck cancer -
Product Epirubicin AqVida 2 mg/ml solution for injection
10 mg, 20 mg, 50 mg, 100 mg, 200 mg vialIndications: Treatment of breast cancer, advanced ovarian cancer, stomach cancer, small cell lung cancer, bladder cancer -
Product Gemcitabine AqVida 38 mg/ml powder for solution for infusion
200 mg, 1 g, 2 g vial Indications: Treatment of NSCLC, pancreatic cancer, bladder cancer, breast cancer -
Product Imatinib AqVida hard capsules*
100 mg, 200 mg, 400 mg capsuleIndications: Treatment of chronic myeloid leukaemia, GIST * Products protected by valid patents are not offered in countries where the sale constitutes a patent infringement.
